Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow X4 Pharmaceuticals, Inc

Get SEC filing alerts via email and in your feed for X4 Pharmaceuticals, Inc

XFOR XFOWW XFORW

X4 Pharmaceuticals, Inc

About X4 Pharmaceuticals, Inc

X4 Pharmaceuticals is a biopharmaceutical company focused on developing oral small-molecule therapies targeting the CXCR4 receptor to treat rare immune system disorders like WHIM syndrome and chronic neutropenia. Its flagship product, mavorixafor (XOLREMDI), is the first FDA-approved drug for WHIM syndrome, aiming to increase circulating immune cells. The company leverages proprietary IP, strategic licensing, and global partnerships to develop and commercialize its innovative treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from X4 Pharmaceuticals, Inc

1
1
X4 Pharmaceuticals, Inc X4 Pharmaceuticals Reports 91% Revenue Decline in Q1 2026, Focuses on Clinical Trials

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
X4 Pharmaceuticals, Inc X4 Pharmaceuticals Reports $35.1 Million Revenue in 2025, Faces $79.2 Million Net Loss

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
X4 Pharmaceuticals, Inc X4 Pharmaceuticals Reports $1.8 Million Revenue in Q3 2025, Net Loss Improves

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
X4 Pharmaceuticals, Inc X4 Pharmaceuticals Reports Revenue Growth but Faces Significant Financial Challenges

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
X4 Pharmaceuticals, Inc X4 Pharmaceuticals Reports $28.8 Million Revenue and Net Income Turnaround in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
X4 Pharmaceuticals, Inc X4 Pharmaceuticals Reports $2.6 Million Revenue from XOLREMDI, Faces $37.5 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
X4 Pharmaceuticals, Inc X4 Pharmaceuticals Reports Financial Developments, Net Loss, and Strategic Sale of Priority Review Voucher

Via official filing (AI summary) | over 1 year ago | 0 comments